WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
sustained release, drug delivery products for treating eye diseases,
today announced that its financial results for the third quarter of
fiscal year 2014 will be released after the market close on Tuesday, May
13, 2014, followed the same day by a conference call and live webcast
scheduled for 4:30 p.m. ET.
The conference call may be accessed by dialing (877) 312-7507 from the
U.S. and Canada, or (631) 813-4828 from international locations. A live
webcast will be available on the Investor Relations section of the
corporate website at http://www.psivida.com.
A replay of the call will be available beginning May 13, 2014, at
approximately 7:30 p.m. ET and ending on May 20, 2014, at 11:59 p.m. ET.
The replay may be accessed by dialing (855) 859-2056 within the U.S. and
Canada or (404) 537-3406 from international locations, Conference ID
Number: 40618782. A replay of the webcast will also be available on the
corporate website during that time.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™,
including Tethadur™. pSivida has instituted the first of two planned
pivotal Phase III clinical trials for its lead development product,
Medidur™, an injectable, sustained release micro-insert for the
treatment of posterior uveitis, a chronic back-of-the-eye disease.
ILUVIEN® for the treatment of chronic DME considered insufficiently
responsive to available therapies, which uses the same micro-insert as
Medidur and is licensed to Alimera Sciences, Inc., is marketed in the
U.K. and Germany and has also received marketing authorization in
Austria, France, Portugal, and Spain and is awaiting authorization in
Italy. Alimera has filed for ten additional EU country approvals through
the Mutual Recognition Procedure. Alimera is seeking approval of ILUVIEN
in the U.S. An investigator-sponsored clinical trial is ongoing for an
injectable, bioerodible micro-insert to treat glaucoma and ocular
hypertension, a product candidate on which Pfizer Inc. has an option.
pSivida's FDA-approved Retisert®, licensed to Bausch & Lomb
Incorporated, provides long-term, sustained drug delivery to treat
posterior uveitis.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: uncertainties
with respect to: ability of STA to achieve marketing approvals, adequate
pricing and reimbursement and market acceptance for and successful
commercialization of ILUVIEN for DME in Australia and New Zealand;
Alimera's ability to finance, achieve additional marketing approvals,
obtain adequate pricing and reimbursement for, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the EU; Alimera's ability to obtain
regulatory approval for, and if approved, to finance, successfully
commercialize and achieve market acceptance of, and generate revenues to
pSivida from, ILUVIEN for DME in the U.S.; the ability to finance,
complete and achieve a successful outcome for Phase III trials for, and
file and achieve marketing approvals for, Medidur for posterior uveitis,
including achieving acceptable risk-to-benefit and safety profiles in
light of the CRL for ILUVIEN; initiation, financing and success of
Latanoprost Product Phase II trials and any exercise by Pfizer of its
option; ability of Tethadur to successfully deliver proteins, peptides
and other large biologic molecules; ability to develop product
candidates and products and potential related collaborations; initiation
and completion of clinical trials and obtaining regulatory approval of
product candidates; continued sales of Retisert; adverse side effects;
ability to attain profitability; ability to obtain additional capital;
further impairment of intangible assets; fluctuations in operating
results; decline in royalty income; ability to, and to find partners to,
develop and market products; termination of license agreements;
competition and other developments affecting sales of products; market
acceptance; protection of intellectual property and avoiding
intellectual property infringement; retention of key personnel; product
liability; consolidation in the pharmaceutical and biotechnology
industries; compliance with environmental laws; manufacturing risks;
risks and costs of international business operations; credit and
financial market conditions; legislative or regulatory changes;
volatility of stock price; possible dilution; absence of dividends; and
other factors described in our filings with the SEC. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Should known or unknown risks materialize,
or should underlying assumptions prove inaccurate, actual results could
differ materially from past results and those anticipated, estimated or
projected in the forward-looking statements. Our forward-looking
statements speak only as of the dates on which they are made. We do not
undertake any obligation to publicly update or revise our
forward-looking statements even if experience or future changes makes it
clear that any projected results expressed or implied in such statements
will not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog: http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
Martin E. Janis & Company, Inc.
Beverly Jedynak, +1 312-943-1123
President
M:
+1 773-350-5793
bjedynak@janispr.com
Source: pSivida Corp.
News Provided by Acquire Media
